Gout Treatments Effective If Patients Maintain Lifelong Adherence to Therapies

Ultimately, educating patients is the key to developing a successful regimen that they will maintain.

References

1. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: Randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study). Arthritis Rheumatol. 2016 Aug 26. doi: 10.1002/art.39840. [Epub ahead of print]
2. Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout.Arthritis Rheumatol. 2016 Aug;68(8):2027–2034. doi: 10.1002/art.39684.
3. Baraf HS, Becker MA, Gutierrez-Urena SR, et al. Tophus burden reduction with pegloticase: Results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26;15(5):R137.
4. Araujo EG, Bayat S, Petsch C, et al. Tophus resolution with pegloticase: A prospective dual-energy CT study. RMD Open. 2015 Jun 17;1(1):e000075.
5. Hemkens LG, Ewald H, Gloy VL, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart. 2016 Apr;102(8):590–596.
6. Singh JA, Yu S. Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Ann Rheum Dis. 2016 Jun 13. pii: annrheumdis-2015-209046.
7. Kohagura K, Tana T, Higa A, et al. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res. 2016 Aug;39(8):593–597.
8. Lolekha P, Wongwan P, Kulkantrakorn K. Association between serum uric acid and motor subtypes of Parkinson’s disease. J Clin Neurosci. 2015 Aug;22(8):1264–1267.